● Covered by 1 source · 2 reportsMedium impact2 negative
RFK Jr. Administration Proposes FDA Ease Access to Unproven Peptide Drugs
Key points
- FDA proposes "Interim Access Policy" for unproven peptide drugs.
- Policy would allow "enforcement discretion" for certain peptides.
- FDA scientists previously found peptides lacked safety/efficacy data.
- Specialty pharmacies could produce these drugs without FDA enforcement.
- Health Secretary Robert F. Kennedy unilaterally passed the rule.
- The rule permits specialty pharmacies to sell six specific peptide drugs.
- The rule is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances”.
- The rule was made available Wednesday on the Federal Register.
- Final publication date for the rule is set for October 30.
- The rule does not change the regulatory status of the peptides.
Proposed Policy for Peptide Drugs
The Food and Drug Administration (FDA) has submitted an "Interim Access Policy" on peptides for review by the White House, according to a filing notice on an Office of Management and Budget website. While details are not public, sources indicate the proposal would grant the FDA "enforcement discretion" regarding certain peptide drugs. This would allow the agency to not enforce current restrictions, providing assurance to specialty pharmacies interested in manufacturing them.
Background on Peptide Regulation
This proposal comes as the FDA is re-evaluating a dozen injectable peptide drugs. In 2023, FDA scientists concluded that these peptides lacked sufficient data to establish their safety and efficacy, identifying potential risks. Consequently, these peptides were removed from the list of drugs that compounding pharmacies are permitted to produce.
Growing Popularity and Claims
Despite the FDA's previous findings, these unproven peptide drugs have gained popularity. Sellers often make unsubstantiated claims about their ability to improve appearance, increase energy, and aid in injury recovery. These products are particularly popular within certain wellness communities, with some prominent figures selling them and Robert F. Kennedy Jr. having expressed support for easing restrictions on peptides.
Potential Impact
If implemented, this policy would significantly alter the regulatory landscape for peptide drugs, potentially making them more widely available through specialty pharmacies. It would represent a shift from the FDA's earlier stance based on scientific assessments of safety and efficacy, allowing drugs previously deemed insufficiently studied to be produced without agency enforcement.
Updates
- Health Secretary Robert F. Kennedy unilaterally passed the rule.
- The rule permits specialty pharmacies to sell six specific peptide drugs.
- The rule is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances”.
- The rule was made available Wednesday on the Federal Register.
- Final publication date for the rule is set for October 30.
- The rule does not change the regulatory status of the peptides.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
The daily brief
One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.
One email a day. Unsubscribe in one click, any time.
Today's brief
Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.
▶ Play today's brief
New every morning, and the back catalogue is archived by date.
How outlets covered it
Health Secretary Robert F. Kennedy unilaterally passed a rule permitting specialty pharmacies to sell six specific peptide drugs, overriding FDA scientists' safety concerns. This action bypasses a 2023 FDA decision to remove these peptides from the list of drugs compounding pharmacies could produce, effectively preventing enforcement actions against their sale.
The Food and Drug Administration (FDA), under Robert F. Kennedy Jr.'s proposed Health Secretary role, is reportedly planning an "Interim Access Policy" for unproven peptide drugs. This policy would grant the FDA "enforcement discretion," allowing specialty pharmacies to produce these drugs despite FDA scientists previously finding insufficient safety and efficacy data and potential risks. The move would reverse a 2023 decision to remove these peptides from the list of drugs compounding pharmacies can make.